Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 -1.38%95 Equity-to-Asset is 0.29 as of Jun. 2026, which is 9% below its 10-year median of 0.32. GuruFocus rates BSP:RADL3 with a GF Score™ of 95/100 and a GF Value™ of R$27.41 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 683 Healthcare Providers & Services companies, Raia Drogasil ranks worse than 73.79% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Raia Drogasil's Total Stockholders Equity for the quarter that ended in Jun. 2026 was R$7,291 Mil. Raia Drogasil's Total Assets for the quarter that ended in Jun. 2026 was R$24,823 Mil.
Therefore, Raia Drogasil's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.29.
The historical rank and industry rank for Raia Drogasil's Equity-to-Asset or its related term are showing as below:
BSP:RADL3'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29 Med: 0.32 Max: 0.53
Current: 0.29
During the past 13 years, the highest Equity to Asset Ratio of Raia Drogasil was 0.53. The lowest was 0.29. And the median was 0.32.
BSP:RADL3's Equity-to-Asset is ranked worse than 73.79% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 0.49
vs BSP:RADL3: 0.29
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Raia Drogasil Equity-to-Asset Related Terms
Raia Drogasil Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Raia Drogasil's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raia Drogasil (BSP:RADL3) has a Equity-to-Asset of 0.29 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Raia Drogasil and its competitors. This is near median its historical median of 0.32. Over the past decade, Raia Drogasil's Equity-to-Asset has ranged from 0.29 to 0.53. According to the industry distribution chart, Raia Drogasil ranks #504 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 73.8%.
Is Raia Drogasil's Equity-to-Asset too high?
Raia Drogasil's current Equity-to-Asset of 0.29 is near median its 10-year median of 0.32. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 0.53. The Healthcare Providers & Services industry median Equity-to-Asset is 0.49. Raia Drogasil's value of 0.29 is 40.8% below this industry median. Based on the distribution chart, Raia Drogasil ranks #504 out of 683 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's Equity-to-Asset compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #504 out of 683 companies for Equity-to-Asset. This places Raia Drogasil in the lower half of its industry. The industry median Equity-to-Asset is 0.49. Raia Drogasil's value of 0.29 is 40.8% below this benchmark. Historically, Raia Drogasil's own Equity-to-Asset has ranged from 0.29 to 0.53 over the past decade. While the company's 10-year median is 0.32 vs. the industry median of 0.49, Raia Drogasil has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.49, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current Equity-to-Asset of 0.29 is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current Equity-to-Asset is 0.29, which is near median its own 10-year median of 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$27.41, compared to a current price of R$19.99 — trading 27.1% below its estimated fair value. The current Equity-to-Asset is 0.29, which is near median its 10-year median of 0.32 and 40.8% below the Healthcare Providers & Services industry median of 0.49. Raia Drogasil's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current Equity-to-Asset is 0.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$19.99 is trading 27.1% below its estimated GF Value™ of R$27.41.
GuruFocus considers Raia Drogasil to be Modestly Undervalued.
Key valuation signals for BSP:RADL3:
Equity-to-Asset: 0.29 (near median its 10-year median of 0.32)
GF Value™: R$27.41 vs. price of R$19.99 (27.1% below fair value)
Industry Position: 40.8% below the Healthcare Providers & Services median (#504 of 683)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
95GF Score
Get the complete analysis for BSP:RADL3
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
